A day after requesting a series of clarifications on another multiple sclerosis drug, NICE said on 6 December in final draft guidance that it intends to recommend Aubagio (Sanofi's teriflunomide) for adults with active relapsing-remitting MS.
There is an appeal period (until 20 December) and then NICE, the health technology assessment body for England and Wales,...